Circulating matrix metalloproteinase-2 is associated with cystatin C level, posttransplant duration, and diabetes mellitus in kidney transplant recipients

Transl Res. 2008 Apr;151(4):217-23. doi: 10.1016/j.trsl.2007.12.004. Epub 2008 Jan 28.

Abstract

Studies have indicated that matrix metalloproteinase-2 (MMP-2) is vital for the patient's condition after renal transplantation. Although the allograft survival rate has been improved, the relationships between various clinical parameters in stable graft function and serum MMP-2 still need to be clarified. In this study, gelatin zymography and enzyme-linked immunosorbent assay were employed to measure MMP-2 level in the plasma of 152 kidney transplant recipients, 41 chronic kidney disease patients, and 50 healthy control subjects. The creatinine and the MMP-2 levels in the transplant recipients were significantly greater (P < 0.001) than those of control subjects. Univariate and stepwise regression analysis demonstrated the MMP-2 level was associated with cystatin C level (P < 0.001), creatinine level (P = 0.036), proteinuria (P = 0.043), posttransplant days (P = 0.025), and posttransplant diabetes mellitus (P = 0.03). We conclude that circulating MMP-2 is associated with cystatin C, posttransplant duration, and diabetes mellitus in kidney transplant recipients and suggest that MMP-2 may be critical for graft survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cystatin C
  • Cystatins / blood*
  • Diabetes Complications*
  • Diabetes Mellitus* / blood
  • Female
  • Humans
  • Kidney Transplantation*
  • Male
  • Matrix Metalloproteinase 2 / blood*
  • Middle Aged
  • Reference Values
  • Time Factors

Substances

  • CST3 protein, human
  • Cystatin C
  • Cystatins
  • Matrix Metalloproteinase 2